Huang Michael F.
Sr. VP of Clinical Development
Huang Michael F. has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 18, 2026.
On the most recent filing, Huang Michael F. is listed as Sr. VP of Clinical Development at SOLENO THERAPEUTICS INC. Inside the rolling window, Huang Michael F. reported no open-market purchases and 1 open-market sale totaling $200K in SLNO.
Companies traded
Other insiders at SLNO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$200K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Huang Michael F. made?
Huang Michael F. has filed 4 SEC Form 4 filings (6 transaction rows) across 1 company since 2025.
Which companies does Huang Michael F. trade?
Huang Michael F. has filed SEC Form 4 disclosures for 1 company, including SLNO.
When was Huang Michael F.'s most recent SEC Form 4 filing?
Huang Michael F.'s most recent SEC Form 4 filing on Tracefour is dated May 18, 2026.
What is Huang Michael F.'s job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Huang Michael F. is listed as Sr. VP of Clinical Development.
What is Huang Michael F.'s total buy and sell value in the current window?
Inside the rolling retention window, Huang Michael F. bought $0 and sold $200K based on SEC Form 4 filings.
What was Huang Michael F.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,582 SLNO shares on 2026-03-27, worth $200K, per SEC Form 4 filings.